Genomics for Health 2024
Genomics for Health 2024
Don’t miss Scailyte’s CEO, Peter Nestorov, at the Genomics for Health event, bridging cutting-edge science and leading industry, organized by the University of Southern Denmark (SDU) and the Danish Institute for Advanced Study (DIAS)!
🗓️ Date: 7th November
📍 Location: DIAS, Odense 🇩🇰
Peter will deliver a compelling presentation titled “Developing clinical biomarkers for immunotherapies using single-cell omics and AI.” He’ll delve into how Scailyte’s innovative platform leverages the power of single-cell analysis and machine learning to uncover groundbreaking biomarkers with the potential to revolutionize immunotherapy treatments.
Peter will be among leading experts translating single-cell and multiomics research into clinical applications, paving the way for more precise and effective healthcare.
🧑🎓 Key speakers:
Tim Aitman from Institute of Genetics and Cancer, University of Edinburgh, UK
Thomas van Overeem Hansen from Hansen Department Clinical Genetics, Rigshospitalet, Copenhagen, Denmark
Marc Sultan from BioX Genetics & Genomics, Roche Innovation Center, Basel, Switzerland
Rachael Natrajan from Functional Genomics, Institute of Cancer, Research, UK
Vivek Das, PhD, M.Sc. from Novo Nordisk, Denmark
Sia Viborg Lindskrog from Department of Clinical, Medicine, Arhus University, Denmark
Anders Borglum from Department of Biomedicine, Aarhus University, Denmark
Elena Papaleo from Danish Cancer Society, Research Center and, Technical University of Denmark
🛜 Beyond his presentation, Peter will be engaging with key industry leaders in Denmark to forge collaborations and drive the advancement of single-cell science in precision medicine. Reach out to Peter Nestorov if you want to partner with Scailyte.
Learn more about the event and register here: https://lnkd.in/dnvwZ48n
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Life Science Industry Meets Data Science Symposium
Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...